NSI-189 Phosphate – 10 Grams Oral Powder (CAS: 1270138-41-4)

$450.00

NSI-189 Phosphate is a synthetic benzylpiperazine-aminopyridine compound and experimental neurogenic molecule. This high-purity lyophilized powder is widely researched for its ability to stimulate hippocampal neurogenesis, enhance synaptic plasticity, and exert antidepressant and pro-cognitive effects. Supplied for laboratory research use only.

Description

NSI-189 Phosphate is a novel chemical entity with the systematic name (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone phosphate . It has a molecular formula of C22H30N4O·H3O4P and a molecular weight of 464.5 Da . NSI-189 was developed by Neuralstem, Inc. based on preclinical data demonstrating stimulation of neurogenesis in human hippocampus-derived neural stem cells in vitro and in mouse hippocampus in vivo . Unlike conventional antidepressants, NSI-189 is independent of monoamine reuptake pathways .

This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.

 

Key Research Focus

NSI-189 has been investigated in preclinical and clinical research exploring its roles in:

  • Hippocampal Neurogenesis and Synaptic Plasticity: NSI-189 stimulates the generation of new neurons in the hippocampus, with regionally specific effects observed largely in the subventricular zone . In acute hippocampal slices, NSI-189 produces time- and dose-dependent increases in long-term potentiation (LTP) magnitude in the CA1 region, a cellular correlate of learning and memory .
  • Antidepressant and Pro-Cognitive Effects: In a Phase 1B multiple-dose escalation study in depressed patients, NSI-189 was relatively well tolerated and showed potential for mitigating depressive symptoms while concurrently improving cognitive function . A Phase 2 double-blind, placebo-controlled study in outpatients with major depressive disorder (MDD) evaluated oral NSI-189 as monotherapy, with findings replicating those of the Phase 1B study and warranting further exploration . A post-hoc analysis suggested NSI-189 selectively benefits moderately depressed patients .
  • Angelman Syndrome (Preclinical Model): In a mouse model of Angelman Syndrome, daily injections of NSI-189 reversed impairments in cognitive and motor functions, with effects associated with activation of the TrkB and Akt signaling pathways . The study concluded that NSI-189 could represent a potential treatment for Angelman Syndrome patients .
  • Diabetic Neuropathy and Mitochondrial Function: NSI-189 enhanced mitochondrial function and reversed peripheral neuropathy and memory impairment in a rat model of type 2 diabetes . Additional research demonstrated amelioration of both central and peripheral neuropathy in mouse models of type 1 and type 2 diabetes .
  • Radiation-Induced Cognitive Dysfunction: Oral administration of NSI-189 demonstrated neuroprotective effects in remediation of radiation-induced cognitive dysfunction in preclinical models .

 

Clinical Development Status

NSI-189 has completed Phase 1 and Phase 2 clinical trials for major depressive disorder. A Phase 2 trial (NCT02695472) evaluated NSI-189 at 40 mg once daily and 80 mg/day (40 mg twice daily) over 12 weeks in approximately 220 subjects . The drug has also received FDA Orphan Drug Designation (647018) . Clinical trial locations were concentrated in the United States, with Neuralstem Inc. as the primary sponsor .

 

Product Specifications

  • Form: Lyophilized Powder (Sterile)
  • Purity: ≥95% (HPLC Verified)
  • Molecular Formula: C22H30N4O·H3O4P
  • Molecular Weight: 464.50 Da
  • CAS Number: 1270138-41-4
  • Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
  • Solubility: Soluble in sterile water or buffer for laboratory use.
  • Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.

 

Why Choose NSI-189 Phosphate?

NSI-189 Phosphate offers a mechanistically distinct research tool for studying hippocampal neurogenesis and synaptic plasticity, operating independently of traditional monoamine pathways . Its demonstrated effects on LTP enhancement, TrkB/Akt pathway activation, and cognitive function reversal in Angelman Syndrome models provide defined molecular targets for experimental design . The availability of Phase 1B and Phase 2 clinical data in MDD offers a translational foundation, and the FDA Orphan Drug Designation supports its research relevance for rare cognitive disorders . Researchers should note that the exact molecular target remains unknown, though the neurogenic mechanism is well-characterized

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.